Chong Kun Dang Holdings

Sky Labs is focused on developing innovative wearable technology for continuous health monitoring, specifically targeting atrial fibrillation, a common but often undiagnosed heart condition. The company’s flagship product, the Cardio Tracker (CART), is a cuffless, ring-type device that allows users to monitor their heart health effortlessly by simply wearing it on their finger. This device is designed to be comfortable and practical for daily use, being waterproof and dustproof so that it can be worn continuously, even during activities like showering. The CART operates without requiring user intervention, automatically detecting and recording instances of atrial fibrillation to provide users with real-time health data accessible via a smartphone app. This capability not only helps users manage their heart health but also assists healthcare professionals in diagnosing atrial fibrillation based on the data collected. Sky Labs is currently engaged in clinical trials with Seoul National University Hospital to validate the device's performance and is collaborating with Bayer to enhance its healthcare offerings. The initial target market includes atrial fibrillation patients in Finland, with a broader goal of reaching millions globally.

# Nodit Nodit is a Web3 development platform specialized in blockchain data. Nodit aims to provide enterprise-grade multi-chain Web3 infrastructure accessible to everyone. By offering reliable node infrastructure with 99.9% uptime and consistent ready-to-query blockchain data at an affordable price, we are facilitating developers’ entry into the Web3 world. # Lambda256 Lambda256, the blockchain tech arm of Dunamu, developed and operates Nodit, which enhances efficiency in managing tasks like blockchain network setup, node operation, and data processing for Ethereum, Arbitrum, and Aptos and Luniverse, a cloud-based blockchain infrastructure platform. Lambda256 also offers a travel rule solution to meet FATF guidelines, improving security and compliance for virtual asset transactions. The company secured Series A funding, followed by Series B funding in December 2021, achieving a total accumulated investment of approximately +80 million USD.

BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

G+FLAS Life Sciences Co., Ltd., founded in 2014 and based in Seoul, South Korea, specializes in agricultural biotechnology with a focus on genome editing applications. Utilizing advanced CRISPR-Cas technology, the company develops innovative products such as glycoengineered humanized plants, which involve the selective removal of glycosylation-related genes. A flagship product is the vitamin D3-enriched tomato, aimed at enhancing nutritional value and addressing market demand for functional foods. This product not only serves the health-conscious consumer but also provides a plant-based alternative to traditional vitamin D supplements, catering to various dietary needs. G+FLAS has established a strategic partnership with Bayer, facilitating the commercialization of its technology and enhancing its position in the agricultural market. The company is also engaged in drug research and development, utilizing its gene therapy expertise to support healthcare organizations and pharmaceutical companies. G+FLAS Life Sciences is well-positioned for growth, targeting significant market share and aiming to accelerate expansion in the U.S. and beyond.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.